Aerobic anti-gravity exercise in patients with Charcot-Marie-Tooth disease types 1A and X:A pilot study by Knak, Kirsten L et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Aerobic anti-gravity exercise in patients with Charcot-Marie-Tooth disease types 1A
and X
Knak, Kirsten L; Andersen, Linda K; Vissing, John
Published in:
Brain and Behavior
DOI:
10.1002/brb3.794
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Knak, K. L., Andersen, L. K., & Vissing, J. (2017). Aerobic anti-gravity exercise in patients with Charcot-Marie-
Tooth disease types 1A and X: A pilot study. Brain and Behavior, 7(12), [e00794].
https://doi.org/10.1002/brb3.794
Download date: 03. Feb. 2020
Brain and Behavior. 2017;7:e00794.	 	 	 | 	1 of 5
https://doi.org/10.1002/brb3.794
wileyonlinelibrary.com/journal/brb3
Received:	26	June	2017  |  Accepted:	2	July	2017
DOI: 10.1002/brb3.794
O R I G I N A L  R E S E A R C H
Aerobic anti-gravity exercise in patients with Charcot–Marie–
Tooth disease types 1A and X: A pilot study
Kirsten L. Knak*  | Linda K. Andersen* | John Vissing
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided the original work is properly cited.
©	2017	The	Authors. Brain and Behavior	published	by	Wiley	Periodicals,	Inc.
*These authors contributed equally to this work.
Copenhagen	Neuromuscular	Center,	
Department	of	Neurology,	Rigshospitalet,	
University	of	Copenhagen,	Copenhagen,	
Denmark
Correspondence
Kirsten	L.	Knak,	Copenhagen	Neuromuscular	
Center,	Department	of	Neurology,	
Rigshospitalet,	University	of	Copenhagen,	
Copenhagen,	Denmark.
Email: kirsten.lykke.knak@regionh.dk
Funding information
Vanførefonden;	Grosserer	L.	F.	Foghts	Fond;	
Familien	Hede	Nielsens	Fond;	Johannes	
Fogs	Fond;	Lundbeckfonden;	Rigshospitalets	
Jubilæumsfond
Abstract
Background: Charcot–Marie–Tooth (CMT) disease is a hereditary neuropathy associ-
ated with impaired walking capacity. Some patients are too weak in the lower extrem-
ity muscles to walk at gravity with sufficient intensity or duration to gain benefit.
Aim: The aim was to investigate the effect of aerobic anti-gravity exercise in weak 
patients	with	CMT	1A	and	X.
Methods:	 Five	 adult	 patients	 performed	 moderate-	intensity	 aerobic	 anti-gravity	
 exercise 3/week for 10 weeks.
Results: There was a significant positive difference in Berg balance scale and postural 
stability	 test	 between	 test	 occasions,	 and	walking	 distance	 in	 the	 6-	min	walk	 test	
trended to increase.
Conclusions: The study indicates that the anti-gravity treadmill training of patients 
with CMT should be pursued in larger CMT cohorts.
K E Y W O R D S
anti-gravity,	Charcot–Marie–Tooth	disease,	exercise
1  | INTRODUCTION
Charcot–Marie–Tooth (CMT) disease is a hereditary neuropathy af-
fecting	motor	and	sensory	nerves.	CMT	type	1A	and	X	present	similar	
phenotypes	and	are	slowly	progressive,	demyelinating	diseases	char-
acterized	by	distal	muscle	weakness,	sensory	loss,	and	joint	deformi-
ties.	There	is	no	effective	treatment	for	CMT	(Jani-	Acsadi,	Krajewski,	
&	Shy,	2008),	but	exercise	is	promising	(Sman	et	al.,	2015).	Effect	of	
walk	training	has	been	investigated	in	CMT	(Maggi	et	al.,	2011;	Wright	
et	al.,	1996),	but	some	patients	are	too	severely	affected	to	walk	with	
gravity at sufficient intensity or duration to obtain benefit. This is 
possible	on	an	anti-gravity	treadmill,	which	off	lifts	load	on	the	lower	
extremities.
The objective was to investigate the effect of aerobic anti-gravity 
exercise in moderately to severely walking disabled patients with CMT 
1A	and	X.
2  | METHODS
2.1 | Patients
Patients	were	recruited	from	our	neuromuscular	center	between	2015	
and 2016. Inclusion criteria were as follows: (1) genetically verified CMT 
type	1A	or	X,	 (2)	≥18	years,	and	 (3)	walking	ability	≥10	m.	Exclusion	
criteria	were	as	follows:	 (1)	compliance	 issues,	 (2)	 	medical	conditions	
that	could	contraindicate	physical	exercise,	(3)		walking		ability	>450	m	
in	a	6-	min	walk	test	(6MWT),	(4)	pregnancy,	(5)		pacemaker,	(6)	aerobic	
exercise	>1	hr/week,	and	(7)	long	transport	time	to	exercise	facilities.
2.2 | Intervention
The study consisted of a 10- week normal daily lives control period 
followed by a 10- week supervised exercise period with walking or 
running	3/week	for	30	min,	consisting	of	5	min	warm-	up	and	25	min	
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moderate	aerobic	intensity	of	70–80%	of	maximum	heart	rate	(HR)	on	
an	anti-gravity	treadmill	(AlterG	Anti-	Gravity	Treadmill	M320).
2.3 | Outcome measures
The primary outcome was the 6MWT. The secondary outcomes were 
(1) postural stability test—overall (PST; Biosway Portable Balance 
System	950-	460),	(2)	clinical	test	of	sensory	integration	and	balance	
(CT-	SIB;	Biosway	Portable	Balance	System	950-	460),	 (3)	 fatigue	se-
verity	scale	 (FSS),	 (4)	short	form	(36)	health	survey	(SF-	36),	 (5)	Berg	
balance	scale	(BBS),	and	(6)	fitness	(Berthelsen	et	al.,	2014).
2.4 | Statistical analyses
Sample size calculations were performed using PS: Power and Sample 
Size	 Calculation	 version	 3.1.2,	 2014	 (Dupont	 &	 Plummer,	 1990).	
Statistics were performed in SPSS Statistics 22. Parametric and non-
parametric analyses were applied as appropriate for intention- to- treat 
(ITT) and per protocol (PP) analyses. ITT analysis was performed on 
the patients from Table 1 who had more than one exercise session. 
The alpha level was p	≤	.05	(see	Data	S1).
2.5 | Ethics
The	study	was	approved	by	the	Capital	Region	Committee	on	Health	
Research	Ethics	 (H-	2-	2014-	095),	and	written	 informed	consent	was	
obtained.
3  | RESULTS
Patient characteristics are described in Table 1. Ten patients were re-
cruited,	 and	 five	 patients	withdrew	 (see	Data	 S2).	One	 patient	 lost	
balance	during	anti-gravity	exercise,	but	completed	the	exercise.	No	
serious adverse events were reported. There was no significant dif-
ference	between	completers	and	dropouts	regarding	age,	body	mass	
index	(BMI),	and	muscle	strength	(p	≥	.267).	Based	on	sample	size	cal-
culations the study was underpowered (see Data S2).
ITT analysis showed a statistically significant difference between 
baseline,	pretest,	midtest,	and	posttest	for	BBS	and	PST,	but	6MWT	
only	trended	to	 increase	 (Figure	1,	Table	2).	The	other	outcomes	did	
not change significantly (see data for all outcomes in Table 3).
4  | DISCUSSION
This small pilot study showed a significant positive change in  balance 
and a trend toward improvement in walking capacity with anti-
gravity	treadmill	training	in	CMT.	This	was	so,	even	though	a	priori	
power calculation suggested a need for including six patients. Post 
hoc analysis of BBS showed a significant difference between baseline 
and	posttest	only,	which	indicates	that	the	difference	was	not	solely	
caused	by	 the	 intervention.	For	PST,	post	hoc	analysis	was	unable	
to detect where the difference between measurements was. This is 
probably due to the reduced power of post hoc multiple comparison 
tests.
TABLE  1 Patient characteristics
Patient/subtype Sex/age/BMI
Smoking/
use of aid Sensory symptoms
Muscle strength (Nm) (hip flex/
ext, knee flex/ext, ankle 
plantarflex/dorsalflex)
Physical activity 
(hours last 7 days)a Status
Patient	1/CMT1A F/62/27 N/none AB	toesb,c,d,e 31/58,	32/60,	6/0 0/0/0/91 Drop out
Patient	2/CMT1A M/53/28 N/none AB	toesb,c,d,e 33/37,	25/69,	48/0 0/0/6/49 Completed
Patient	3/CMTX M/64/21 N/ankle foot 
orthoses
NAb,c,d,	AB	SIASe 46/66,	44/118,	0/0 3/1/7/28 Completed
Patient	4/CMT1A F/62/28 N/
orthopedic 
shoes
AB	toesb,c,d,	AB	
cruse
29/65,	26/58,	7/0 0/ND/5.25/ND Completed
Patient	5/CMT1A M/31/34 N/insoles AB	toesb,c,	NAd,	AB	
malleoluse
93/168,	90/163,	49/29 0/2.3/1.5/56 Completed
Patient	6/CMT1A F/50/28 N/
orthopedic 
shoes
NAb,c,	AB	toesd,	AB	
kneee
53/147,	58/121,	13/6 0.5/2/4.5/70 Completed
Patient	7/CMTX M/46/23 Y/ankle foot 
orthoses
AB	toesb,	AB	
kneec,	AB	
malleolusd,	AB	
SIASe
84/124,	64/196,	8/0 0//0/7/84 Drop out
F,	female;	M,	male;	BMI,	body	mass	index	(kg/m2);	Y,	yes,	N,	no;	NA,	nothing	abnormal;	AB,	abnormal;	ND,	not	determined;	SIAS,	Spina	iliaca	anterior	su-
perior;	Nm,	Newton	meter.
aExhaustive exercise/moderate exercise/walking/sitting.
bProprioception.
cSensation.
dPain.
eVibration.
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ITT	 and	 PP	 analyses	 showed	 similar	 results	 for	 all	 outcomes,	
except for BBS (ITT p	=	.021,	 PP	 p = .121). ITT is more conser-
vative,	 thus,	 it	 is	more	difficult	 to	detect	 a	possible	effect,	 but	 the	
result might be explained by dropouts that reduce the power in PP 
compared to ITT.
One patient increased the walking distance in the 6MWT with 
approximately 100 m between each test occasion from baseline to 
posttest,	which	is	a	remarkably	difference	questioning	the	credibility	of	
the	results.	The	patient’s	post-	HR	after	6MWT	was	similar	for	baseline,	
pre-	,	 and	midtest	 (post-	HR:	 114–117),	 but	 increased	 substantially	 at	
posttest	 (post-	HR:	167).	Thus,	at	 least	some	of	the	increased	walking	
distance at posttest is explained by a learning effect with greater physi-
cal	effort	at	retest.	A	learning	effect	for	6MWT	has	previously	been	doc-
umented	for	NMDs	(Knak,	Andersen,	Witting,	&	Vissing,	2017;	Prahm,	
Witting,	&	Vissing,	2014).	Caution	should	be	exercised	when	applying	
HR	as	an	indicator	of	physical	effort	in	training	studies,	as	HR	is	influ-
enced	by	fitness,	but	this	is	primarily	of	relevance	if	HR	is	reduced	after	
the	aerobic	intervention,	which	was	not	the	case	in	the	present	patient.	
Results	did	not	change	when	the	outlier	was	excluded,	although	p- value 
for	6MWT,	excluding	the	outlier,	was	near	.05	in	PP	analysis.
F IGURE  1 Berg	balance	scale	(BBS),	postural	stability	test	(PST),	and	6-	min	walk	test	(6MWT)	at	test	occasion	(intention-	to-	treat	[ITT]).	
Circle	and	asterisk	are	outliers	1.5–3.0	and	>3.0	box	length	from	edge,	respectively
TABLE  2 Change	in	6MWT,	BBS,	and	PST	between	test	
occasions (ITT)
6MWTa BBSb PSTb
Baseline–pretest 17 ± 17 0	(−6;8) 0	(−.5;.3)
Baseline–midtest 71	±	38 4	(0;5) −.2	(−.7;0)
Baseline–posttest 92	±	53 3 (2;12) −.2	(−.6;0)
Pretest–midtest 54	±	25 4	(0;5) −.2	(−.4;0)
Pretest–posttest 75	±	39 8	(1;10) −.1	(−.4;0)
Midtest–posttest 21 ± 16 2 (0;6) 0 (0;.1)
6MWT,	6-	min	walk	test	(m);	BBS,	Berg	balance	scale	(score);	PST,	postural	
stability	test	(index);	ITT,	intention-	to-	treat	analysis.
aMean ± standard error of the mean.
bMedian	(25th;75th	percentile).
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The	 temporary	 pain	 in	 two	 patients	 might	 be	 due	 to	 overload,	
since the patients did not perform regularly aerobic exercise prior to 
the	study,	and	there	was	no	run-	in	period	with	progression	of	aerobic	
intensity.
A	study	(Wright	et	al.,	1996)	in	CMT	indicated	that	walking	on	
the	ground	was	well-	tolerated	and	may	improve	aerobic	capacity,	
and Maggi et al. (2011) indicated that walking on a normal tread-
mill	 combined	 with	 stretching,	 respiratory,	 and	 proprioceptive	
exercises improved walking capacity without overwork weakness 
in CMT. Berthelsen et al. (2014) showed effect of anti-gravity 
strength and aerobic exercises on walking capacity and balance in 
weak patients with muscular dystrophies. Compared to the pres-
ent	underpowered	pilot	study,	aerobic	capacity	was	not	improved,	
balance	assessments	showed	mixed	results,	walking	capacity	indi-
cated	a	trend	toward	improvement,	and	two	patients	experienced	
temporary	 pain.	 Thus,	 further	 studies	 are	 needed	 to	 assess	 the	
true magnitude of the effect of anti-gravity training in patients 
with marked muscle weakness.
The	study	was	limited	by:	 (1)	 lack	of	sufficient	power,	 introducing	
a	possible	type	II	error,	(2)	small	sample	limiting	the	generalizability,	(3)	
retesting	by	several	investigators,	and	(4)	accessibility	of	the	anti-gravity	
treadmill is limited.
In	conclusion,	our	pilot	study	showed	a	significant	positive	change	
in	balance	and	a	trend	toward	improvement	in	walking	capacity,	sug-
gesting that anti-gravity treadmill training of hereditary neuropathies 
should be pursued in a larger cohort of patients.
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